EFGCP Broadens Support for Investigator-initiated Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
EFGCP Broadens Support for Investigator-initiated Trials

Source: Applied Clinical Trials

The complex legal, regulatory, financial and organizational requirements are not widely known in the investigator, hospital and university communities engaged in clinical research, according the European Forum for GCP. To address the issue, it is running a two-day workshop, called Striving for Professionalism in Investigator-initiated trials (IITs), to be held in Brussels, Belgium, on February 26-27.

The legal conditions for academic sponsorship vary from country to country, which makes the organization of multinational trials even more difficult, noted a statement from EFGCP. Treatment optimization, exploration of new indications, head-to-head comparison of new medicines, investigation of long-term treatment outcomes and/or efficiency of treatments are important tasks for the medical community.

“Like for pharma company-initiated trials the overall responsibility for the trials lies also in IITs with the sponsor. But in contrast to privately sponsored studies the infrastructure to fulfil these sponsor obligations is not always available in an academic environment,” the organizers wrote.

The workshop aims to bring together investigators, academic organizations, hospital and university administration representatives, regulators, ethics committee members, lawyers, pharmaceutical companies, and patient representatives. The focus will be on different sponsor tasks and business models, contracting and training, and the aim is to produce recommendations for facilitating and harmonizing the framework and organization for IITs.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here